CFM
MDGL icon

Catalyst Funds Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Catalyst Funds Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$321K Buy
+613
New +$293K 0.05% 336
2024
Q2 		– Sell
-300
Closed -$80.1K – 1420
2024
Q1 		$80.1K Buy
+300
New +$70.7K 0.02% 452

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Catalyst Funds Management's MDGL Position: Q1 2026 in Review

Catalyst Funds Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q1 2026: 613 shares worth $321K. The stake represents 0.05% of the portfolio and ranks #336 among its holdings. This is a return to the name: Catalyst Funds Management previously reported a position in MDGL as recently as Q1 2024.

Catalyst Funds Management first reported a position in MDGL in Q1 2024 and has held it in 2 quarters since. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Catalyst Funds Management held 613 shares of Madrigal Pharmaceuticals worth $321K as of Q1 2026.
  • Madrigal Pharmaceuticals was a new Catalyst Funds Management position in Q1 2026.
  • Madrigal Pharmaceuticals made up 0.05% of Catalyst Funds Management's portfolio in Q1 2026, its #336 holding.
  • Catalyst Funds Management first reported a position in Madrigal Pharmaceuticals in Q1 2024 and has held it in 2 quarters since.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.